Rule clarification.The photo with the most ‘likes’ by Friday wins. If you want to support someone else you can post a photo, and say in the text who you are supporting instead of yourself. We then add up the likes. Top 2 go into a vote run off if it’s close Shilpa Gupta Toni Choueiri, MD

ESMO has announced the recipients of the 2023 ESMO Society Awards based on recognition of their work in strengthening the oncology field and providing support to fellow oncologists in their professional careers.
📌ow.ly/rvam50PgY7U

Just out in JAMA Oncology NIVOREN GustaveRoussy ancillary study  Félix Lefort Corticosteroids use impact in pts with mRCC under nivolumab: longer PFS&OS - 2 potential explanations (i)steroid mainly for IrAEs, selected stronger immune response (ii)persistent signif. immortal time bias

#KCRS23 #Mentorship panel discussion ! Honored to take part Toni Choueiri, MD Tom Powles Hans Hammers Rana McKay Sumanta K. Pal, MD, FASCO Renee Maria Saliby Nazli Dizman

Pleased to share The Lancet Oncology LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim ESMO - Eur. Oncology #ESMO22 and final Chung-Han Lee 李宗翰, MD/PhD ASCO #ASCO23

full text: authors.elsevier.com/a/1hP1c5EIIgLp…
Thanks to all who change
rareRCC pts Tx!

Last few days to apply for an ESMO Research Fellowship.

It could be your chance to develop high-quality research projects in translational or clinical research.

📌Application deadline: 19 June 2023
👉ow.ly/fg0450OJTqA

#OncologyResearch

Outstanding presentation by ylt GustaveRoussy of THOR study : Erdafitinib vs chemo in mUC with FGFR alterations previously treated. OS benefit (12 vs 8 months, HR 0.64, p=0.005). Molecular testing at metastatic stage in all patients is essential +++ #ASCO2023

Flawless presentation by Toni Choueiri, MD at #ASCO23 of #CONTACT03 results. We didn’t sleep much over the past several weeks putting this manuscript together for simultaneous pub in The Lancet! Thank you to Katy Beckermann & Brian Rini, MD for a terrific editorial accompanying the…

.Prism Center selected to receive 30-40 M euros to build a Precision Oncology Center. Vision: to classify pts based on biology. Scientific strategy: bottom-up approach to model cancer biology in each pt (fig 2) for early cancer or relapse detection, & tt optimisation (fig 3).

1/ Results from #COSMIC -313 are out NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by Charles Swanton Andres Cervantes #ESMO22

Thread 🧵==>

nejm.org/doi/full/10.10…

Best performers systemic therapy for #papillaryRCC by Pr M Schmidinger - seminal works from
Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Cris Tom Powles Sylvie Negrier, Alain Ravaud , Bernard Escudier GETUG GustaveRoussy

A 55 years journey in #sarcomatoidRCC - the understanding and the remaining challenges summarized by B.C. Leibovich MD Mayo Clinic Kidney Cancer #IKCSEU23
A major step forward with IO based regimens for all of us treating these patients thanks to Pr N TANNIR MD Anderson Cancer Center

Internes d’Urologie et d’Oncologie, ne ratez pas la soirée-formation sur le cancer du rein organisée par l’AERIO et l’AFUF qui aura lieu à la Maison de l’Urologie le 30 mai !

Lien de l’évènement : facebook.com/events/s/soire…

AERIO 😷💉💉💉 Arnaud Méjean, MD, PhD AFU Laurence Albiges

Fantastic Sarah P. Psutka MD MS to start the surgical session #IKCSEU23 ! everything one needs to know about surveillance in Small Renal Mass: A must see for med Onc to use in Tumor Board !@KidneyCancer Viktor Grünwald European Urology Karim Bensalah Marc-Olivier Timsit, MD, PhD AFU